NCT07527806 2026-04-14
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
Clinical Trials
31 trialsNCT07528898 2026-04-14
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07413939 2026-04-09
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
NCT07518173 2026-04-08
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07402473 2026-02-11
EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Not yet recruiting
NCT07366840 2026-01-26
BRIGHT
Fudan University
Phase 2/3 Not yet recruiting
NCT07332533 2026-01-12
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT07299890 2025-12-23
An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT07136428 2025-12-19
ASCENdANT
Duke University
Phase 1/2 Not yet recruiting
NCT07246317 2025-11-28
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07245797 2025-11-24
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC
Fudan University
Phase 2 Not yet recruiting
NCT07220135 2025-10-23
NeoTHERa
University of Kansas Medical Center
Phase 2 Not yet recruiting
NCT06027983 2025-09-23
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
National University Hospital, Singapore
Phase 1/2 Not yet recruiting
NCT07187752 2025-09-23
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
Shandong Cancer Hospital and Institute
Phase NA Not yet recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07093931 2025-07-30
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
Shandong Cancer Hospital and Institute
Phase 4 Not yet recruiting
NCT06998771 2025-05-31
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT06589830 2025-05-15
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
Phase 2 Not yet recruiting
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT06510465 2024-07-19
NeoURANIA
RenJi Hospital
Phase 2 Not yet recruiting
NCT06439550 2024-06-03
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT05983094 2023-08-09
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05901935 2023-06-13
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT05841381 2023-05-03
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University
Phase 3 Not yet recruiting
NCT05388500 2022-05-27
PHARE-C
Institut de cancérologie Strasbourg Europe
Phase 3 Not yet recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting
NCT04973319 2021-07-22
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Shengjing Hospital
Phase 3 Not yet recruiting
NCT04922008 2021-06-10
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Fudan University
Phase 2 Not yet recruiting
NCT04337658 2020-04-08
FAVOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Not yet recruiting
NCT04158856 2019-11-12
SHERO
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting